Innate Immunity in Bullous Pemphigoid
Innate Immunity in Bullous Pemphigoid
批准号:
7987670
负责人:
Zhi Liu
金额:
$35.56万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-15 至 2015-04-30
关键词:
AddressAutoantibodiesAutoimmune ProcessAutoimmunityBP180 autoantigenBindingBullaBullous PemphigoidC5a anaphylatoxin receptorCell DegranulationChemotactic FactorsChymaseCleaved cellComplementComplement 5aDataDermalDevelopmentDiseaseEotaxinEventExtracellular DomainExtracellular MatrixFeedbackGelatinase BGoalsHumanIL8 geneIgEIgE ReceptorsIgG ReceptorsImmuneImmune responseImmune systemImmunoglobulin GIn VitroInfiltrationInflammationInflammatory InfiltrateInjection of therapeutic agentInjuryInterleukin-5LesionLeukocyte ElastaseLymphocyteMediatingMediator of activation proteinMinorModelingMouse StrainsMusNatural ImmunityNeonatalNeutrophil InfiltrationOryctolagus cuniculusParticipantPathway interactionsPatientsPeptide HydrolasesPositioning AttributeProcessProteinsRecruitment ActivityResearchResistanceRoleSiteSkinStaining methodStainsSystemTestingTissuesWidespread DiseaseWorkanti-IgGcrosslinkdisease mechanisms studydisease phenotypeeffective therapyeosinophilhuman CCL26 proteinin vivokeratinocytemast cellmouse modelneutrophilpreclinical studypublic health relevanceskin disorder
中文摘要
描述(由申请方提供):大疱性类天疱疮(BP)是一种自身免疫性表皮下水疱性疾病,其特征为自身抗体和病变部位的炎性浸润。BP自身抗体属于IgG和IgE同种型,并识别两种半桥粒蛋白,BP 180和BP 230。体外和体内研究已经证明抗BP180自身抗体固定补体并且是致病的。NC16A是BP180的胞外结构域,是致病性自身抗体的主要靶标。嗜酸性粒细胞通常是突出的,真皮浸润也含有中性粒细胞,肥大细胞和淋巴细胞。然而,这些关键的先天免疫参与者的作用仍然未知。缺乏可用的体内系统是使用患者来源的自身抗体研究BP中先天免疫应答的主要障碍。我们的实验室目前开发了人源化BP180小鼠染色剂(称为NC16A小鼠),其中小鼠BP180NC14A结构域被人BP180NC16A结构域取代。更重要的是,注射了抗BP180自身抗体的新生NC16A小鼠发生了模拟BP关键免疫学特征的皮肤病。本建议的目的是研究嗜酸性粒细胞和肥大细胞在BP中的作用,使用我们新开发的NC16A小鼠模型。该项目的总体目标是增加我们对BP先天免疫的理解,以及它如何与炎症和自身免疫中先天免疫系统参与者的功能相关。在目标1中,我们将确定BP是否需要肥大细胞。目的二是研究嗜酸性粒细胞在BP中的作用,并探讨嗜酸性粒细胞与肥大细胞之间的相互作用。目的3:研究嗜酸性粒细胞和肥大细胞蛋白水解酶在BP水疱中的作用。由于该提案整合了疾病机制研究和临床前试验,预计这些发现将对BP患者的治疗产生重大影响。
公共卫生相关性:大疱性类天疱疮(BP)是最常见和潜在致命的自身免疫性水疱疾病。我们将研究疾病发展的过程,并确定更有效治疗的新靶点。
英文摘要
DESCRIPTION (provided by applicant): Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease characterized by autoantibodies and an inflammatory infiltrate at the lesional site. BP autoantibodies belong to IgG and IgE isotypes and recognize two hemidesmosomal proteins, BP180 and BP230. In vitro and in vivo studies have demonstrated that anti- BP180 autoantibodies fix complement and are pathogenic. NC16A, an extracellular domain of BP180, is the primary target of pathogenic autoantibodies. Eosinophils are usually prominent, and the dermal infiltrate also contains neutrophils, mast cells and lymphocytes. However, roles of these key innate immune players remain unknown. Lack of a usable in vivo system is a major obstacle for studies of innate immune responses in BP using patient-derived autoantibodies. Our lab currently developed a humanized BP180 mouse stain (termed NC16A mice), in which the mouse BP180NC14A domain is replaced by the human BP180NC16A domain. More significantly, neonatal NC16A mice injected with anti-BP180 autoantibodies develop skin disease that mimics key immunological features of BP. The objective of this proposal is to study the role of eosinophils and mast cells in BP using our newly developed NC16A mouse model. The overall goal of this project is to increase our understanding of the innate immunity of BP and how it relates to the functions of innate immune system players in inflammation and autoimmunity. In Aim 1, we will determine whether mast cells are required for BP. Aim 2 is to study the role of eosinophils and to determine functional interaction between eosinophils and mast cells in BP. In Aim 3, we will study the role of proteolytic enzymes of eosinophils and mast cells in BP blistering. Since this proposal integrates both disease mechanism studies and preclinical trials, the findings are expected to have a significant impact on the treatment of patients with BP.
PUBLIC HEALTH RELEVANCE: Bullous pemphigoid (BP) is the most common and potentially fatal autoimmune blistering disease. We will study the process of the disease development and identify new targets for more effective therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of a salt-based nanomedicine for non-muscle invasive bladder cancer
-
批准号:10482565
-
项目类别:
-
资助金额:$39.99万
-
财政年份:2022
-
负责人:Zhi Liu
-
依托单位:
Development of a radiation-activatable nanoparticle for lung cancer therapy
-
批准号:10259278
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2021
-
负责人:Zhi Liu
-
依托单位:
Inflammasome-gasdermin axis in bullous pemphigoid
-
批准号:10382402
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2018
-
负责人:Zhi Liu
-
依托单位:
Inflammasome-gasdermin axis in bullous pemphigoid
-
批准号:9899921
-
项目类别:
-
资助金额:$38.99万
-
财政年份:2018
-
负责人:Zhi Liu
-
依托单位:
Eosinophils in Bullous Pemphigoid
-
批准号:10198769
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2017
-
负责人:Zhi Liu
-
依托单位:
Innate Immunity in Bullous Pemphigoid
-
批准号:8073124
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2010
-
负责人:Zhi Liu
-
依托单位:
Innate Immunity in Bullous Pemphigoid
-
批准号:8261445
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2010
-
负责人:Zhi Liu
-
依托单位:
Innate Immunity in Bullous Pemphigoid
-
批准号:8461644
-
项目类别:
-
资助金额:$34.43万
-
财政年份:2010
-
负责人:Zhi Liu
-
依托单位:
The Mechanism of IVIG Action in Pemphigus
-
批准号:6890262
-
项目类别:
-
资助金额:$32.44万
-
财政年份:2004
-
负责人:Zhi Liu
-
依托单位:
The Mechanism of IVIG Action in Pemphigus
-
批准号:6811119
-
项目类别:
-
资助金额:$35.35万
-
财政年份:2004
-
负责人:Zhi Liu
-
依托单位:
The Mechanism of IVIG Action in Pemphigus
-
批准号:7050144
-
项目类别:
-
资助金额:$32.08万
-
财政年份:2004
-
负责人:Zhi Liu
-
依托单位:
Immunopathogenesis of Bullous Pemphigoid
-
批准号:8447124
-
项目类别:
-
资助金额:$35.72万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
IMMUNOPATHOGENESIS OF BULLOUS PEMPHIGOID
-
批准号:2442724
-
项目类别:
-
资助金额:$10.5万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
Immunopathogenesis of Bullous Pemphigoid
-
批准号:7686342
-
项目类别:
-
资助金额:$33.08万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
IMMUNOPATHOGENESIS OF BULLOUS PEMPHIGOID
-
批准号:2887364
-
项目类别:
-
资助金额:$5.4万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
IMMUNOPATHOGENESIS OF BULLOUS PEMPHIGOID
-
批准号:2672922
-
项目类别:
-
资助金额:$10.5万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
Immunopathogenesis of Bullous Pemphigoid
-
批准号:9067884
-
项目类别:
-
资助金额:$38.0万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
IMMUNOPATHOGENESIS OF BULLOUS PEMPHIGOID
-
批准号:2077274
-
项目类别:
-
资助金额:$10.43万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
IMMUNOPATHOGENESIS OF BULLOUS PEMPHIGOID
-
批准号:6895570
-
项目类别:
-
资助金额:$25.46万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
IMMUNOPATHOGENESIS OF BULLOUS PEMPHIGOID
-
批准号:6608189
-
项目类别:
-
资助金额:$25.46万
-
财政年份:1996
-
负责人:Zhi Liu
-
依托单位:
海外基金